Shashank Cingam
@shashankcingam
BBMT/CellTherapy Physician @ Ochsner-LSU FWCC | Fellowship @StanfordBMT_CT|Tweets, RT’s are personal opinions and not endorsements
ID: 817971825678438400
08-01-2017 05:50:55
82 Tweet
175 Takipçi
310 Takip Edilen
653. Clinical and Epidemiological: Decluttering Responses and Dynamic Risk: How Can We Improve Prognostication in MM ? Join us 9:30 AM for some thought-provoking abstracts ASH Joushua Gustine Xinhe Shan Rahul Banerjee, MD, FACP and may more #mmsm MCW Cancer Center #ASH24
#ASH24 looking forward to this excellent session about how to make myeloma #MMsm response assessments work better! Meera Mohan Shashank Cingam as the awesome moderators!
#ASH24 Impressive real-world data from the Greek myeloma group suggesting that sustained MRD negativity for 3 years can guide discontinuation of lenalidomide maintenance, probably except in patients with +2 high risk cytogenetics. #mmsm Thanos Dimopoulos
Honored to have delivered our abstract as an oral presentation at ASH '24. Teclistamab can be given safely and effectively in the community bringing the drug more directly to the patients who need it! HealthTree Foundation Aimaz Afrough UTSW Simmons Cancer Center Larry Anderson,MD,PhD,FACP Flatiron Health
An very important white paper summarizing thoughts from different stakeholders including academia, FDA, and others from a workshop that debated every aspect of Drug Development in #MDSsm kudos to authors led by myeloid malignancy rising star Alain Mina ashpublications.org/bloodadvances/…
Dr. Punita Grover University of Minnesota showing ⬆️ chronic #GVHD with #PTCy/siro/MMF vs PTCy/tac/MMF in a sequential phase II well matched myeloablaive study setting ⚡️#Tandem25
